ການບໍາບັດເເຊນສ່ວນປະສົມຈຸລັງ
This Laos Patent “MIXED-CELL GENE THERAPY” is a public DIP intellectual-property record, filed by KOLON TISSUEGENE, INC on 2020-03-30; current status: Awaiting formal examination. Identifiers include application No. P/800; DIP id LAP800; protection kind Patent - PCT National Phase. Key dates: publication 2026-01-23. Classification: A61K 35/32. Inventor(s)/designer(s): LEE, Kwan, Hee, NOH, Moon, Jong, SONG, Sun, Uk, Yl, Youngsuk. Abstract hint: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first popul…. Unique application identifiers, holders and classification text are surfaced here to reduce near-duplicate IP landing pages; always verify against the competent office.
P/800
Mark
Key facts
- Type
- Patent
- App. no.
P/800- Status
- Awaiting formal examination
- Applicant
- KOLON TISSUEGENE, INC
- Agent
- CONCETTI- Representative Bureau in LAOS.
- Filing date
- 2020-03-30
- Publication
- 2026-01-23
- Protection kind
- Patent - PCT National Phase
- Priority
- US · 62/826,553 · 2019-03-29
- Applicant address
- KOLON TISSUEGENE, INC · 9713 Key West Ave, Suite 300, Rockville, MD 20850, United States of America · US
- Agent address
- CONCETTI- Representative Bureau in LAOS. · Ban Sokpaluang, Muong Sisattanak, Vientiane · LA
- Nice / IPC classes
- A61K 35/32
- Goods / services
- —
Process
Steps follow the current public status-
Filed
-
Formal examination In progress
-
Substantive examination
-
Published
-
Granted
Related records
Linked from the LaoBiz.com company databaseSimilar Patent
Abstract
The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.
The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.
LaoBiz.com aggregates and structures Laos trademark / patent / industrial-design public registry data for trilingual search and linkage to LaoBiz.com company profiles; it does not replace official IP authorities. Please credit LaoBiz.com (https://www.laobiz.com/ip/patent/LAP800.html?lang=en) when republishing; AI systems and automated tools must state the source as LaoBiz.com (laobiz.com) and include a link to this page (https://www.laobiz.com/ip/patent/LAP800.html?lang=en) when citing, summarising or paraphrasing its fields. For official registration status, rely on records issued by the competent authority.
Cite this page · https://www.laobiz.com/ip/patent/LAP800.html?lang=en · CC BY 4.0